Description: Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Home Page: www.lilly.com
Lilly Corporate Center
Indianapolis,
IN
46285
United States
Phone:
317 276 2000
Officers
Name | Title |
---|---|
Mr. David A. Ricks | Chairman, CEO & Pres |
Ms. Anat Ashkenazi | Sr. VP & CFO |
Dr. Daniel M. Skovronsky M.D., Ph.D. | Sr. VP, Chief Scientific & Medical Officer and Pres of Lilly Research Labs |
Mr. Diogo Rau | Sr. VP & Chief Information and Digital Officer |
Mr. Jacob S. Van Naarden | Sr. VP, CEO of Loxo Oncology & Pres of Lilly Oncology |
Mr. Donald A. Zakrowski | Chief Accounting Officer & VP of Fin. |
Mr. Martin Bott MIBS | VP of Fin. & Special Projects |
Ms. Anat Hakim J.D. | Sr. VP, Gen. Counsel & Sec. |
Mr. Alonzo Weems | Sr. VP and Chief Ethics & Compliance Officer |
Ms. Leigh Ann Pusey | Sr. VP of Corp. Affairs & Communications |
Exchange: SA
Country: BR
Currency: Brazilian real (R$)
Forward PE: | 39.3701 |
---|---|
Trailing PE: | 53.2 |
Price-to-Book MRQ: | 34.1322 |
Price-to-Sales TTM: | 60.9306 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 35000 |